SCHEMBL331065

SCHEMBL331065

CCCCCCCC[N+](C)(C)C.Cc1ccc(S(=O)(=O)[O-])cc1

nearest known ligand 0.59

Known targets — ChEMBL curated mechanism

CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
CYP2C9 P11712 3/20 0.59
KCNH2 Q12809 2/20 0.59
CYP2D6 P10635 2/20 0.59
CYP2C19 P33261 2/20 0.59
TSHR P16473 2/20 0.59
HTT P42858 1/20 0.59
HIF1A Q16665 1/20 0.59
DNM1 Q05193 6/20 0.50
MCHR1 Q99705 1/20 0.49
NR1I2 O75469 1/20 0.48
APAF1 O14727 1/20 0.47
HSP90AA1 P07900 1/20 0.47
RAD52 P43351 1/20 0.47
CYP3A4 P08684 2/20 0.46
MAPK1 P28482 1/20 0.46
THPO P40225 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 3/20 0.42
BBOX1 O75936 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL330681 1.00 LMNA (0.59) LMNACYP2C9KCNH2CYP2D6CYP2C19
SCHEMBL2181552 1.00 LMNA (0.59) LMNACYP2C9KCNH2CYP2D6CYP2C19
SCHEMBL2181688 1.00 LMNA (0.59) LMNACYP2C9KCNH2CYP2D6CYP2C19
SCHEMBL31327346 1.00 LMNA (0.59) LMNACYP2C9KCNH2CYP2D6CYP2C19
SCHEMBL699895 1.00 LMNA (0.59) LMNACYP2C9KCNH2CYP2D6CYP2C19
SCHEMBL8723514 1.00 LMNA (0.59) LMNACYP2C9KCNH2CYP2D6CYP2C19
SCHEMBL31327347 1.00 LMNA (0.59) LMNACYP2C9KCNH2CYP2D6CYP2C19
Cetrimonium SCHEMBL121980 1.00 LMNA (0.59) LMNACYP2C9KCNH2CYP2D6CYP2C19
Cetrimonium SCHEMBL5678134 0.98 KCNH2 (0.57) LMNACYP2C9KCNH2CYP2D6CYP2C19
Cetrimonium SCHEMBL28609304 0.98 KCNH2 (0.57) LMNACYP2C9KCNH2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11929257-B2 Etching solution and method for aluminum nitride VERSUM MATERIALS US, LLC (US) 2024-03-12 US claimed
US-20220367199-A1 ETCHING SOLUTION AND METHOD FOR ALUMINUM NITRIDE VERSUM MATERIALS US, LLC (US) 2022-11-17 US claimed
EP-3959291-A1 ETCHING SOLUTION AND METHOD FOR ALUMINUM NITRIDE Versum Materials US, LLC (US) 2022-03-02 EP claimed
WO-2020185745-A1 ETCHING SOLUTION AND METHOD FOR ALUMINUM NITRIDE VERSUM MATERIALS US, LLC (US) 2020-09-17 WO claimed
EP-1812382-B1 METHOD FOR PRODUCING POLYISOCYANATES BASF SE (DE) 2013-01-23 EP claimed
US-20090112017-A1 METHOD FOR PRODUCING POLYISOCYANATES BASF AKTIENGESSELLSCHAFT (DE) 2009-04-30 US claimed
US-20080305157-A1 Encapsulation and separation of charged organic solutes inside catanionic vesicles UNIVERSITY OF MARYLAND OFFICE OF TECHNOLOGY COMMERCIALIZATION (US) 2008-12-11 US claimed
EP-1812382-A1 METHOD FOR PRODUCING POLYISOCYANATES BASF AKTIENGESELLSCHAFT (DE) 2007-08-01 EP claimed
WO-2006048171-A1 METHOD FOR PRODUCING POLYISOCYANATES BASF AKTIENGESELLSCHAFT (DE) 2006-05-11 WO claimed
US-20250154607-A1 ISOTHERMAL AMPLIFICATION OF PATHOGENS BECTON, DICKINSON AND COMPANY 2025-05-15 US disclosed
US-20250059586-A1 NON-OPAQUE LYTIC BUFFER COMPOSITION FORMULATIONS BECTON, DICKINSON AND COMPANY 2025-02-20 US disclosed
US-20250059612-A1 METHOD FOR SEPARATING GENOMIC DNA FOR AMPLIFICATION OF SHORT NUCLEIC ACID TARGETS BECTON, DICKINSON AND COMPANY 2025-02-20 US disclosed
EP-4473127-A1 METHOD FOR SEPARATING GENOMIC DNA FOR AMPLIFICATION OF SHORT NUCLEIC ACID TARGETS Becton, Dickinson and Company (US) 2024-12-11 EP disclosed
EP-4473128-A1 NON-OPAQUE LYTIC BUFFER COMPOSITION FORMULATIONS Becton, Dickinson and Company (US) 2024-12-11 EP disclosed
WO-2009013062-A1 PROCESS FOR THE SYNTHESIS OF CARBAMATES USING CO2 HUNTSMAN INTERNATIONAL LLC (US) 2009-01-29 WO disclosed
EP-2011782-A1 Process for the synthesis of carbamates using co2 HUNTSMAN INTERNATIONAL LLC (US) 2009-01-07 EP disclosed
US-20080305157-A1 Encapsulation and separation of charged organic solutes inside catanionic vesicles UNIVERSITY OF MARYLAND OFFICE OF TECHNOLOGY COMMERCIALIZATION (US) 2008-12-11 US disclosed
EP-1812382-A1 METHOD FOR PRODUCING POLYISOCYANATES BASF AKTIENGESELLSCHAFT (DE) 2007-08-01 EP disclosed
WO-2006048171-A1 METHOD FOR PRODUCING POLYISOCYANATES BASF AKTIENGESELLSCHAFT (DE) 2006-05-11 WO disclosed
US-5165994-A Spontaneous equilbrium surfactant vesicles UNIVERSITY OF DELAWARE (US) 1992-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090112017-A1 METHOD FOR PRODUCING POLYISOCYANATES PGLS, INMT, PNMT LMNA 1276/4885CYP2C9 565/4885KCNH2 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.